Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory DiseasesSAN FRANCISCO, March 29, 2023 (GLOBE NEWSWIRE) -- Third...
Clinical Trial
Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of...
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical...
BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research,...
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company...
Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs
BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months...
Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study
Third generation drug substance manufacturing process increases the final yield of nomacopan by at least 5-fold, improving cost efficiencies in...
Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need
Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net salesEquity investment by Théa Open...
G MEDICAL INNOVATIONS AND ADVENTHEALTH IN JOINT COLLABORATION TO PROVIDE INNOVATIVE REMOTE PATIENT MONITORING SOLUTIONS FOR ADVENTHEALTH PATIENTS IN CENTRAL FLORIDA
Rehovot, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical...
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming...
Avalo Reports 2022 Financial Results and Provides Business Updates
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second...
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced...
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most...
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied...
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic...
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
Mainz Biomed’s proprietary nucleic acid extraction and PCR process proved to be highly effectiveTwo mRNA biomarkers found to be particularly...
Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update
Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate developmentPartnering momentum...
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt
AD Ports Logistics, subsidiary of AD Ports Group’s Logistics Cluster, chosen as the Exclusive Distributor for United Arab Emirates, Qatar,...